The Mission Report

Marcum MicroCap Conference
June 1-2, 2016 - Grand Hyatt Hotel, New York, NY

The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.

Presenting Companies: June 1st June 2nd


SLOT 1 – 9am

CohBar (CWBR)

CohBar (OTC: CWBR) researches and develops of mitochondria-based therapeutics (MBTs), an emerging class of drugs for the treatment of diseases associated with aging. MBTs originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. This discovery was made by CohBar founders, pioneers in the biology of aging, metabolism and mitochondrial genomics. MBTs offer the potential to address a broad range of diseases such as Type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders. For more information, visit the company's website at

Endonovo Therapeutics (ENDV)

Endonovo Therapeutics (OTC: ENDV) is a biotech company developing a bioelectronic approach to regenerative medicine. The company's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating and preventing vital organ failure through the reduction of inflammation and the promotion of regeneration. Endonovo is initially concentrating on treating acute inflammatory conditions in the liver using this technology. Endonovo's Cytotronics™ platform is designed to expand and optimize the therapeutic potential of stem cells and for the production of fully human biomolecules. The company is initially concentrating on the creation of next generation cell therapies that have been enhanced using bioelectronics for the treatment of Graft-Versus-Host Disease (GvHD). For more information, visit the company's website at

Global Self Storage, Inc. (SELF)

Global Self Storage, Inc. (NASDAQ: SELF) is a self-administered, self-managed real estate investment trust ("REIT") focused on the ownership, operation, acquisition, development and redevelopment of self storage facilities in the United States. Global Self Storage's facilities are designed to offer affordable, easily accessible and secure storage space for residential and commercial customers. The company currently owns and operates, through its wholly owned subsidiaries, seven self storage properties located in New York, Pennsylvania, Illinois, Indiana and South Carolina. For more information, visit the company's website at

NioCorp Developments (NIOBF)

NioCorp Developments (OTC: NIOBF) is developing a superalloy materials project in Southeast Nebraska that will produce niobium, scandium and titanium. Niobium is used to produce superalloys, as well as High Strength, Low Alloy ("HSLA") steel, which is a lighter, stronger steel used in automotive, structural and pipeline applications. Scandium is a superalloy material that can be combined with aluminum to make alloys with increased strength and improved corrosion resistance. Scandium is also a critical component of advanced solid oxide fuel cells, while titanium is used in various superalloys and is a key component of pigments used in paper, paint and plastics and is also used for aerospace applications, armor and medical implants. For more information, visit the company's website at

Provectus Biopharmaceuticals (PVCT)

Provectus Biopharmaceuticals (OTC: PVCT) specializes in developing oncology and dermatology therapies. Its novel investigational drug for cancer, PV-10, is designed for injection into solid tumors, thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and liver cancers. The company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase II trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis. For more information, visit the company's website at

SG Blocks (SGBXQ)

SG Blocks (OTC: SGBXQ) is an innovator of commercial and private environments utilizing code-engineered cargo shipping containers. Providing solutions to some of the world's biggest companies and government agencies, SG Blocks offers cost effective container-construction technology that exceeds many standard building code requirements. The company works with developers, architects, builders and owners to achieve faster execution, stronger high-value buildings, and greener construction. For more information, visit the company's website at

SLOT 2 – 9:30am

Biostage (BSTG)

Biostage (NASDAQ: BSTG) is a biotech company in the emerging field of regenerative medicine. The company's goal is to regenerate and restore organ function of the esophagus, trachea or bronchus damaged by cancer, trauma, infection or congenital diseases. Using its Cellframe technology, Biostage has been developing a new generation of organ implants capable of being used in the esophagus and main airways (trachea and bronchi). The company is expanding its preclinical data in collaboration with the Mayo Clinic and intends to submit an IND with the FDA for its first indication in 2016. For more information, visit the company's website at

Midwest Energy Emissions (MEEC)

Midwest Energy Emissions (OTC: MEEC) delivers patented and proprietary solutions to the global coal-power industry to remove mercury from power plant emissions. The EPA requires that all U.S.-based coal- and oil-fired power plants, larger than 25 mega-watts, must remove roughly 90% of mercury from their emissions. Midwest Energy's patented technology and proprietary products have been shown to achieve mercury removal levels at significantly lower cost and less operational impact than currently used methods, while preserving the marketability of fly-ash for beneficial use. For more information, visit the company's website at

NanoViricides (NNVC)

NanoViricides (NYSE: NNVC) is a pre-clinical biotech company that has utilized its patented platform technology to rapidly create anti-viral drug candidates. The company has conducted tests on more than 6,000 animals infected with various strains of influenza, HIV, dengue/dengue hemorrhagic fever, Ebola, rabies, adenovirus of the eye as well as herpes infections of the skin and the eye without evidence of resistance, side effects or toxicity. Treatments for various forms of acute herpes infections are now being advanced through the pre-clinical process toward human trials. For more information, visit the company's website at

PharmaCyte Biotech (PMBC)

PharmaCyte Biotech (NASDAQ: PMBC) is a clinical stage biotechnology company that develops treatments for cancer and diabetes using a proprietary cellulose based live cell encapsulation known as "Cell-in-a-Box®." PharmaCyte cancer treatment encapsulates genetically modified live cells, which can convert an inactive chemotherapy drug (ifosfamide) into its "cancer-killing" form. The encapsulated live cells are placed as close to a cancerous tumor as possible, then the patient is intravenously given ifosfamide at one-third normal dose. When ifosfamide comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. PharmaCyte is also developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes using the Cell-in-a-Box® technology. For more information, visit the company's website at

Provision Interactive Technologies, Inc. (PVHO)

Provision Interactive Technologies, Inc., a subsidiary of Provision Holding, Inc. (OTC: PVHO), is the leading purveyor of intelligent interactive 3D holographic display technologies, software and integrated solutions for both commercial and consumer-focused applications. Provision's 3D holographic display systems represent a revolutionary technology that provides the projection of full color, high-resolution videos into space detached from the screen, without any special glasses. Provision is currently the market leader in true 3D consumer advertising display products being implemented by innovative, consumer-focused companies. For more information, visit the company's website at

SLOT 3 – 10am

CombiMatrix Corp. (CBMX)

CombiMatrix Corp. (NASDAQ: CBMX) provides molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. The company specializes in prenatal diagnostics, miscarriage analysis /recurrent pregnancy loss, pediatric genetics and pre-implantation genetic screening, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. For more information, visit the company's website at

CorMedix (CRMD)

CorMedix (NYSE: CRMD) is an emerging commercial-stage biopharmaceutical company that initiated a phase 3 clinical study of a novel anti-infective solution in hemodialysis patients. The company's strategy is to seek to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world. For more information, visit the company's website at

Inventergy Global, Inc. (INVT)

Inventergy Global, Inc. (NASDAQ: INVT) is an intellectual property company focused on identifying, acquiring and licensing the patented technologies of market-significant technology leaders. The company leans on decades of corporate experience, market and technology expertise, and industry connections to help clients leverage the value of their innovations to achieve greater returns. Inventergy acquires portfolios in the telecommunications industry, primarily in IP multimedia subsystems and voice over IP, and mobile broadband communications segments. For more information, visit the company's website at

Legacy Education Alliance (LEAI)

Legacy Education Alliance (OTC: LEAI) offers comprehensive instruction and mentoring, primarily on the topics of real estate and financial instruments investing, through its Rich Dad Education brand. The company delivers its programs through various channels, including live courses, online trainings, coaching, mentoring programs, and multi-media products that impart skills and knowledge in real estate investing, financial instrument investing, entrepreneurship, and personal finance. For more information, visit the company's website at

SLOT 4 – 10:30am

BG Staffing (BGSF)

Headquartered in Plano, Texas, BG Staffing (NYSE: BGSF) is a national provider of temporary staffing services across a diverse set of industries. Through both organic growth and accretive acquisitions, the company has grown revenue to $217 million in 2015 (approximately 25% increase over 2014) from approximately $40 million in 2010. The company pays a $0.25 quarterly dividend. Company president and CEO L. Allen Baker, Jr. has been in the staffing industry since 1985, having made more than 20 successful acquisitions throughout his career. At BG Staffing, Baker has closed and successfully integrated seven accretive acquisitions. For more information, visit the company's website at

BIO-key International (BKYI)

BIO-key International (OTC: BKYI) provides of fingerprint biometric identification, secure mobile credentialing, and user identity verification solutions to reduce risk and protect the value of their services and assets. BIO-key's products are software-based and optimized to deliver fast and accurate user authentication on any device, network or Internet environment. These software products are compatible with more than 50 fingerprint readers. The company's technology is standards-compliant, independently validated by the National Institute of Standards & Technology (NIST), and hardware and operating system agnostic. For more information, visit the company's website at

BioRestorative Therapies (BRTX)

BioRestorative Therapies (OTC: BRTX) develops therapeutic products primarily using adult stem cells. The company's lead cell therapy candidate is formulated from autologous cultured mesenchymal stem cells for the non-surgical treatment of chronic lumbar disc disease. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and potentially face the prospect of surgery. BioRestorative Therapies is also developing an allogeneic cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to regulate metabolic homeostasis in humans. For more information, visit the company's website at


CEL-SCI (NYSE: CVM) is primarily focused on R&D to improve the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy, Multikine, is currently being studied in a pivotal global phase 3 clinical trial, and is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for rheumatoid arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu. For more information, visit the company's website at

SLOT 5 – 11am

Antibe Therapeutics (ATBPF)

Antibe Therapeutics (OTC: ATBPF) develops medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. For more information, visit the company's website at

General Employment Enterprises, Inc. (JOB)

General Employment Enterprises, Inc. (NYSE: JOB) provides specialized staffing solutions, operating in two industry segments: providing professional staffing services and solutions in the information technology, engineering, finance and accounting specialties and light industrial staffing services through the names of General Employment, Access Data Consulting, Agile Resources, Ashley Ellis, Omni-One, Paladin Consulting and Triad. Also, in the healthcare sector, General Employment, through its Scribe Solutions brand, staffs medical scribes who assist physicians in emergency departments of hospitals and in medical practices by providing required documentation for patient care in connection with electronic medical records (EMR). For more information, visit the company's website at

PCM, Inc. (PCMI)

PCM, Inc. (NASDAQ: PCMI) (formerly known as PC Mall, Inc.) is a technology solutions provider to businesses, government and educational institutions and individual consumers. The company markets its products, services and solutions through a 700+ sales force, field service teams, and various direct marketing techniques. PCM offers multi-branded hardware solutions with a high degree of customization, and also facilitates an efficient supply chain and support mechanism for manufacturers by using a combination of direct marketing, centralized selling and support, and centralized product fulfillment. For more information, visit the company's website at

Pulmatrix (PULM)

Pulmatrix (NASDAQ: PULM) is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its clinically validated, proprietary iSPERSE technology. The company's PUR0200 is a branded generic in clinical development for chronic obstructive pulmonary disease. Pulmatrix's proprietary product pipeline is focused on advancing treatments for rare diseases, including an inhaled anti-fungal for patients with cystic fibrosis. For more information, visit the company's website at

Q BioMed (QBIO)

Q BioMed (OTC: QBIO) is a biomedical acceleration and development company that is focused on acquiring undervalued biomedical assets. Q BioMed is dedicated to providing these target assets, strategic resources, developmental support, and expansion capital to accelerate development and, ultimately, to provide much needed products‏. The company intends to maximize risk-adjusted returns by focusing on clinical stage and innovative products where the technical, regulatory and commercial risks have been mitigated or major valuation inflections are imminent. For more information, visit the company's website at

Relmada Therapeutics (RLMD)

Relmada Therapeutics (OTC: RLMD), a clinical-stage biopharmaceutical company, develops novel versions of proven drug products combined with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The company has four lead products at various stages of development: d-Methadone (REL-1017), its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028), its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. For more information, visit the company's website at

SLOT 6 – 11:30am

Bridgeline Digital, Inc. (BLIN)

As The Digital Engagement Company™, Bridgeline Digital's (NASDAQ: BLIN) strategy is to help customers maximize the performance of their full digital experience – from websites and intranets to online stores and campaigns. The company's iAPPS platform deeply integrates web content management, eCommerce, eMarketing, social media management, and web analytics to help marketers deliver digital experiences that attract, engage and convert their customers across all channels. Headquartered in Burlington, Massachusetts, Bridgeline has thousands of customers that range from small- and medium-sized organizations to Fortune 1000 companies. For more information, visit the company's website at

Moleculin Biotech (MBRX)

Moleculin Biotech (NASDAQ: MBRX) recently priced its IPO and expects to trade under the symbol MBRX. The company is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Its lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. For more information, visit the company's website at

PeerLogix (LOGX)

PeerLogix (OTC: LOGX) is a data aggregation company using proprietary software to enable the tracking and cataloguing of Torrent files and Torrent networks to determine consumer trends and preferences based upon media consumption. PeerLogix's patent pending platform collects Torrent data, including IP addresses, the name, file type, media type and genre of media downloaded, and utilizes licensed and publicly available demographic and other databases to further filter the collected data to provide insights into consumer preferences to digital advertising firms, product and media companies, entertainment studios and others. For more information, visit the company's website at

PURE Bioscience (PURE)

PURE Bioscience (OTC: PURE) is commercializing its patented antimicrobial products (FDA-approved PURE Control® and EPA registered PURE® Hard Surface) providing less toxic and more effective food safety solutions for food processors/manufacturers, retailers and restaurants. Test data demonstrate PURE's products' superior efficacy over a broad spectrum of pathogens, including E. coli, salmonella, listeria and norovirus, when compared with toxic products currently in use in the food industry. The growing U.S. food-safety-solutions industry is a $2+ billion total opportunity and it is PURE's 3–5 year goal to achieve at least 10+ % share of these markets to prevent foodborne illnesses. For more information, visit the company's website at

Soligenix (SNGX)

Soligenix (OTC: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company has two active business segments. The BioTherapeutics segment is developing a photo-dynamic therapy for the treatment of cutaneous T-cell lymphoma, and proprietary formulations for the prevention/treatment of gastrointestinal disorders. The Vaccines/BioDefense segment has active development programs for a ricin toxin vaccine, an anthrax vaccine, OrbeShield, a GI acute radiation syndrome therapeutic candidate, and SGX943, a melioidosis therapeutic candidate. For more information, visit the company's website at

SLOT 7 – 2pm

Astro-Med, Inc. (ALOT)

Astro-Med, Inc., d/b/a AstroNova (NASDAQ: ALOT) designs, manufactures, distributes and services a broad range of products that acquire, store, analyze and present data in multiple formats. The company's Product Identification segment offers a variety of hardware and software products and associated consumables that allow customers to mark, track and enhance the appearance of their products. The Test and Measurement segment includes the T&M Product Group, which offers a suite of products and services that acquire and record electronic signal data from local and networked sensors; and a line of Aerospace Products used in aircraft flight decks and cabins to record, print and display data. For more information, visit the company's website at

eWellness Healthcare (EWLL)

eWellness Healthcare (OTC: EWLL) is the first physical therapy telemedicine company to offer real-time, insurance reimbursable distance monitored treatments. The company's business model is to license its PHZIO ("PHZIO") platform to any physical therapy clinic in the U.S. and/or have large-scale employers use our PHZIO platform as a fully PT monitored corporate wellness program. PHZIO re-defines the way physical therapy can be delivered. The technology is the first of its kind physical therapy platform for home use. Due to the real-time patient monitoring feature, the PHZIO platform is insurance reimbursable by payers such as Anthem Blue Cross and Blue Shield. For more information, visit the company's website at

ImmunoCellular Therapeutics, Ltd. (IMUC)

ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) is a Los Angeles-based clinical-stage company developing immune-based therapies for the treatment of brain and other cancers. The company has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. Other candidates in the ImmunoCellular pipeline include: ICT-121, a dendritic cell vaccine targeting CD133; ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer killing T-cells. For more information, visit the company's website at

Microlin Bio (MICBE)

Microlin Bio (OTC: MICBE) is an emerging therapeutics company focused on microRNA and its role in oncology. MicroRNAs are recently discovered, naturally occurring RNA molecules that do not encode proteins, but instead regulate gene expression and various biological pathways. Improper balance of microRNAs is believed to be linked to many diseases, including cancer. The company has agreements to exclusively license a portfolio of approximately 100 issued and pending patents and patent applications covering numerous microRNAs and a novel delivery technology for potential use in the development of its therapeutic product candidates. For more information, visit the company's website at

Pyxis Tankers (PXS)

Pyxis Tankers (NASDAQ: PXS) owns a modern fleet of six tankers engaged in the seaborne transportation of refined petroleum products and other bulk liquids. The company is focused on growing its fleet of medium range product tankers, which are designed to provide operational flexibility and enhanced earnings potential due to their "eco" features and modifications. Pyxis believes it is well-positioned to opportunistically expand and maximize its fleet due to its competitive cost structure, strong customer relationships and experienced management team, whose interests are aligned with company shareholders. For more information, visit the company's website at

SLOT 8 – 2:30pm

Car Charging Group (CCGI)

Car Charging Group (OTC: CCGI) is a pioneer in nationwide public electric vehicle (EV) charging services that enable EV drivers to easily recharge at locations throughout the United States. Headquartered in Miami Beach, Florida, Car Charging Group also has offices in San Jose, California; New York, New York; and Phoenix, Arizona. The company's business model is designed to accelerate the adoption of public EV charging. Through its subsidiary, Blink Network, CarCharging also provides residential EV charging solutions for single-family homes. For more information, visit the company's website at

Emerald Medical Applications (MRLA)

Emerald Medical Applications (OTC: MRLA) owns the Dermacompare Medical App, a cloud-based, artificial intelligence technology that enables photos, taken from almost all digital cameras, to detect the suspicion of melanoma. The FDA-registered, HIPPA-compliant app, available from any App store, enables the user to identify suspicious melanoma moles automatically by comparing the photos to Emerald's cloud database of over 50 million known moles, as well as the patient's previous pictures. For more information, visit the company's website at

Great Basin Scientific (GBSN)

Great Basin Scientific (NASDAQ: GBSN) is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. Great Basin's vision is to make molecular diagnostic testing simple and cost-effective enough that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. For more information, visit the company's website at


IZEA, Inc. (NASDAQ: IZEA) has created and operates an online marketplace designed to connect brands with influential content creators. IZEA's content creators range from leading bloggers and social media personalities to A-List celebrities and professional journalists. These creators are compensated for developing and distributing unique content on behalf of brands including long-form text, videos, photos and status updates. Conversely, brands receive influential consumer content and engaging, shareable stories that drive awareness. For more information, visit the company's website at

Spring Bank Pharmaceuticals (SBPH)

Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. For more information, visit the company's website at

SLOT 9 – 3pm

Dataram (DRAM)

Dataram (NASDAQ: DRAM) is an independent manufacturer of memory products and provider of performance solutions that increase the performance and extend the useful life of servers, workstation, desktops and laptops sold by leading manufacturers. Dataram's memory products and solutions are sold worldwide to OEMs, distributors, value-added resellers and end users. Seventy Fortune 100 companies are powered by Dataram. The company's mission is to deliver solutions that improve the performance of clients' computing environment, lower their total cost of ownership, and leverage their investment in technology. For more information, visit the company's website at

EyeGate Pharma (EYEG)

EyeGate Pharma (NASDAQ: EYEG) is a late-stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery mechanisms for treating diseases of the eye. The company's technology addresses two of the most prevalent issues in ophthalmic care: the existing lack of patient adherence, and patient safety. EyeGate Pharma is committed to advancing its delivery technology and therapeutic candidates with a goal of bringing new, potentially superior treatment options to patients who will most likely benefit. For more information, visit the company's website at


NXT-ID (NASDAQ: NXTD) is an emerging technology company focused on products, solutions, and services for security on mobile devices. Its core technologies consist of those that support digital payments, biometric identification, encryption, sensors, and miniaturization. The company is pursuing three lines of business: mobile commerce, primarily through the application of secure digital payment technologies; biometric access control applications, and Department of Defense contracting. Initial efforts have primarily focused on the development of secure products for the growing m-commerce market, such as its secure mobile electronic smart wallet. For more information, visit the company's website at

TapImmune (TPIV)

TapImmune (OTCQB: TPIV) is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases. The company's peptide or nucleic acid-based immunotherapeutics comprise one or more naturally processed epitopes designed to comprehensively stimulate patients' T-cells while restoring or further augmenting antigen presentation. TapImmune's technologies are suitable for use as stand-alone medications, as well as in combination with current treatment modalities. For more information, visit the company's website at

SLOT 10 – 3:30pm

Cellectar Biosciences (CLRB)

Cellectar Biosciences (NASDAQ: CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer-targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated phase 1 study in patients with relapsed or refractory multiple myeloma. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a pre-clinical stage product candidate, with plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information, visit the company's website at

Integrity Applications (IGAP)

Integrity Applications (OTC: IGAP) is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Applications operates primarily through its wholly owned Israeli subsidiary, A.D. Integrity Applications, Ltd. The company has developed the GlucoTrack® model DF-F, a technology intended for use in non-invasive quantitative spot measurement of glucose, for home-use. The GlucoTrack model DF-F has been proven for safety and performances for patients in clinical studies conducted by third party, under the supervision of leading diabetes authorities at the Soroka University Medical Center in Israel. The upgraded device gained a CE-Mark approval in December 2015. For more information, visit the company's website at


PAVmed (NASDAQ: PAVMU) is a multi-product medical device company developing and commercializing a diversified pipeline of innovative products which address unmet clinical needs. The company's goal is to enhance and accelerate value creation by employing a business model focused on capital efficiency and speed to market. PAVmed is building a deep development product pipeline with attractive regulatory pathways and market opportunities encompassing a broad spectrum of clinical areas including carpal tunnel syndrome, medical infusions, interventional radiology, tissue ablation, and cardiovascular intervention. For more information, visit the company's website at


For more frequent updates, follow us on Twitter!

Home     About Us     Blog     Investors     IR Services     Market Research     Partners     Contact     Disclaimer

© 2016 Mission Investor Relations. All rights reserved.
3645 Marketplace Blvd.   Suite 130-280   Atlanta, GA 30344   404-941-8975